
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc is positioned for substantial growth, reflected in its current enterprise value of approximately $430 million, which indicates significant upside potential of 8-10 times the share price if its partnership with Novoproves yields positive results. The company's management expresses confidence in executing Phase 1 trials more efficiently for candidates like SEP-786, leveraging their prior experience, which bodes well for future advancements in its drug development efforts. Additionally, the promising preclinical results for SEP-631, which has the potential to match the efficacy of Xolair and achieve blockbuster status, further enhance the company's outlook by suggesting that it may offer an improved therapeutic profile.
Bears say
Septerna Inc faces significant risks that could hinder its clinical development, particularly concerning delays in advancing its product candidates like SEP-631 and potential setbacks in clinical trials. The company's reliance on partnerships, especially with Novo Nordisk, adds further uncertainty, along with challenges in obtaining regulatory approvals and lower-than-anticipated market penetration rates for its therapies. Furthermore, concerns about long-term dilution risk and a recent transaction in the obesity sector highlight a potential valuation gap that may negatively impact investor sentiment.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares